← Every company
Intellia Therapeutics Inc Patents
What Intellia Therapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
NTLA on carbonthat →Filings on file
55
Granted
3
Still pending
52
Filed under
2 names
55 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| Compositions, Methods, and Systems for Genomic EditingC12N 9/226, C12N 15/113, C12N2310/20, C07K2319/09, C12N 9/1252, C12N 9/22, C12N 15/102, C12N 15/11, C12N 15/115, C12N 15/907, C12N2310/16, C12N2310/315, C12N2310/318, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/344, C12N2310/3519, C12N2310/3521, C12N2310/3531, C12N2310/3533, C12N2310/531, C12Y 207/07007Filed as Intellia Therapeutics, Inc.2026-05-07Sabin Mulepati | pending |
| Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentA61P 25/00, C12N 15/113, C12N 15/907, C12N2310/20, A61P 25/28, C12N 9/226, A61K 31/713, A61K 38/00, A61K 48/00, C12N 9/22, C12N 15/11, C12N 15/63, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/346, C12N2310/3515, C12N2310/3521, C12N2320/11, C12N2320/30, C12N2320/31, C12N2320/32, C12N2320/51, C12N2800/80Filed as Intellia Therapeutics, Inc.2026-03-26Yong Chang | pending |
| CD70 CAR-T Compositions and Methods for Cell-based TherapyA61P 35/00, C07K 16/2875, C12N2310/20, A61P 35/02, A61K 40/00, A61K 40/4232, A61K 40/15, A61K 40/31, A61K 40/50, A61K 40/11, C12N 9/226, A61K 35/17, A61K 39/00, C07K 14/7051, C07K 14/70517, C07K2317/53, C07K2317/565, C07K2317/622, C07K2319/03, C07K2319/33, C12N 5/0636, C12N 5/0646, C12N 15/113, C12N 15/62, C12N 15/8645, C12N 15/867, C12N 15/88, C12N2510/00, C12N2740/15043, C12N2750/14143Filed as Intellia Therapeutics, Inc.2026-02-10Michael Lam | pending |
| Compositions and Methods for Genetically Modifying Transforming Growth Factor Beta Receptor Type 2 (TGFßR2)C12N 5/0636, C12N 15/11, C12N 15/1138, C12N2310/20, A61K 40/4232, A61K 40/30, A61K 40/32, A61K 40/31, A61K 40/11, C12N 9/226, A61K2039/53, A61K2039/55555, C07K 14/7051, C07K 14/70539, C12N 15/88, C12N 15/907, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/3521, C12N2310/531, C12N2320/11, C12N2510/00Filed as Intellia Therapeutics, Inc.2026-02-10Michael Lam | pending |
| Compositions and Methods for Genetically Modifying CD70C12N 15/11, C12N 15/1138, C12N2310/20, A61P 35/00, A61K2239/38, A61K 40/4224, A61K 40/31, A61K 40/11, C12N 9/226, A61K 35/00, C07K 16/00, C07K 16/2875, C12N 5/0636, C12N 15/88, C12N 15/907, C12N2320/11, C12N2510/00, C12N2310/321, C12N2310/3521, C12N2310/315, C12N2310/344Filed as Intellia Therapeutics, Inc.2026-02-10Michael Lam | pending |
| Polynucleotides, Compositions, and Methods for Genome EditingC12N 9/222, C12N 9/226, C12N 9/22, C12N 15/09, C12P 19/34, C12N2310/20, A61K 9/5123, A61K 48/0041, A61K 48/0066, C07K2319/09, C12N 15/102, C12N 15/11, C12N 15/111, C12N 15/113, C12N 15/85, C12N 15/88, C12N2320/32, C12N2800/80Filed as Intellia Therapeutics, Inc.2026-01-02Christian Dombrowski | pending |
| ASSAYS FOR ANALYSIS OF RIBONUCLEIC ACID (RNA) MOLECULESC12Q 1/6813Filed as Intellia Therapeutics, Inc.2025-12-12Christine Kitsos | pending |
| LIPID NANOPARTICLES COMPOSITIONS WITH RIBONUCLEOPROTEINSFiled as INTELLIA THERAPEUTICS, INC.2025-11-26CHRISTOPHER BLANCHARD | pending |
| IONIZABLE AMINE LIPIDSC07C 271/20, A61K 9/5123, A61K 31/7105, A61K 38/465, A61K 48/0033, A61K 48/0041, A61K 48/005, C07D 295/13Filed as Intellia Therapeutics, Inc.2025-11-18Ramsey Nabil Majzoub | pending |
| POLYPEPTIDES, POLYNUCLEOTIDES, COMPOSITIONS, AND METHODS FOR GENOME EDITING INVOLVING CHROMATIN REMODELERSFiled as INTELLIA THERAPEUTICS, INC.2025-11-03SABIN MULEPATI | pending |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESC12N 15/113, C12N2310/20, A61P 7/06, A61P 7/00, C12N 9/226, A61K 31/713, A61K 48/005, C12N 9/22, C12N 15/102, C12N2310/10, C12N2320/11Filed as INTELLIA THERAPEUTICS, INC.2025-10-21Craig Stephen MICKANIN | pending |
| Compositions and Methods for ImmunotherapyA61K 48/0058, C12N 15/111, C12N 15/907, C12N2310/20, A61P 35/00, C12N 9/226, C07K 14/705, C07K 14/7051, C12N 9/22, C12N 15/1138, C12N2310/315, C12N2310/321, C12N2310/322, C12N2320/30, C12N2750/14143Filed as Intellia Therapeutics, Inc.2025-10-14Amy Melissa Becker | pending |
| IONIZABLE AMINE LIPIDSC07C 229/12, C12N2310/20, C12N 9/226, A61K 9/1272, A61K 9/5123, A61K 31/7105, A61K 31/713, A61K 45/06, A61K 47/18, A61K 47/22, A61K 48/0025, C07C 219/06, C07C 219/16, C07C 219/20, C07C 229/26, C07C 229/30, C07C 233/36, C07C 233/47, C07C 271/12, C07C 271/20, C07C 275/14, C07C 311/05, C12N 9/22, C12N 15/102, C12N 15/111, C12N 15/113, C12N 15/907Filed as Intellia Therapeutics, Inc.2025-10-09Rubina Giare Parmar | pending |
| Compositions and Methods for Treating Alpha-1 Antitrypsin DeficiencyA61K 9/14, C12N 15/113, C12N2310/20, A61P 43/00, A61P 1/16, A61P 11/00, A61K 9/1271, A61K 9/5146, A61K 47/24, A61K 47/28, A61K 48/005, C12N 9/22, C12N 15/102, C12N 15/86, C12N 15/907, C12N2310/315, C12N2310/321, C12N2310/344, C12N2310/346, C12N2310/3521, C12N2320/32, C12N2320/51Filed as Intellia Therapeutics, Inc.2025-10-08Shobu Odate | pending |
| COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCYC12N 15/113, C12N 15/62, C12N 15/90, C12N2310/20, A61P 1/16, A61P 1/18, A61P 11/00, C12N 9/226, A61K 48/00, A61K 48/005, C07K 14/8125, C12N 9/22, C12N 15/102, C12N 15/1137, C12N 15/86, C12N 15/907, C12N2320/32, C12N2750/14143, C12N2800/80Filed as Intellia Therapeutics, Inc.2025-09-23Jonathan Douglas Finn | pending |
| Compositions and Methods for Kallikrein (KLKB1) Gene EditingC12N 9/226, C12N 15/113, C12N2310/20, A61P 43/00, A61K 31/712, A61K 31/7125, A61K 48/0066, C12N 9/22, C12N 15/102, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3521Filed as Intellia Therapeutics, Inc.2025-09-17Shobu Odate | 12674151 |
| Compositions and Methods for Kallikrein (KLKB1) Gene EditingC12N 9/226, C12N 15/113, C12N2310/20, A61P 43/00, A61K 31/712, A61K 31/7125, A61K 48/0066, C12N 9/22, C12N 15/102, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3521Filed as Intellia Therapeutics, Inc.2025-09-12Shobu Odate | pending |
| CISH COMPOSITIONS AND METHODS FOR IMMUNOTHERAPYFiled as Intellia Therapeutics, Inc.2025-09-05Birgit Schultes | pending |
| Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use ThereofA61P 25/00, A61K 31/573, A61K 48/005, C12N2310/20, A61P 25/28, C12N 9/226, A01K2207/15, A01K2217/052, A01K2227/105, A01K2267/0306, A61K 31/135, A61K 31/138, A61K 31/167, A61K 31/341, A61K 31/7105, A61K 31/7115, A61K 31/7125, A61K 31/713, A61K 45/06, A61K 48/00, A61K2300/00, B82Y 5/00, B82Y 30/00, C12N 9/22, C12N 15/113, C12N 15/88, C12N 15/907, C12N2310/315, C12N2310/321, C12N2310/344, C12N2310/346, C12N2310/3521, C12N2320/11, C12N2320/31, C12N2320/51Filed as Intellia Therapeutics, Inc.2025-08-08Yong Chang | pending |
| Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)C07H 21/02, C12N 15/11, C12N 15/113, C12N2310/20, C12N 9/226, C07K 14/475, C07K 14/521, C12N 9/22, C12N 15/63, C12N2830/50Filed as Intellia Therapeutics, Inc.2025-07-22Christian Dombrowski | pending |
| Modified Guide RNAsC12N 15/11, C12N 15/113, C12N2310/20, A61P 43/00, A61P 35/00, C12N 9/222, C12N 9/22, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/346, C12N2310/3521, C12N2310/3525, C12N2310/3533, C12N2310/531, C12N2320/51Filed as Intellia Therapeutics, Inc.2025-07-01Amy Madison Rhoden Smith | 12735698 |
| MODIFIED GUIDE RNAS FOR GENOME EDITINGFiled as INTELLIA THERAPEUTICS, INC.2025-06-25SABIN MULEPATI | pending |
| Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)C12N 15/113, C12N 15/1137, C12N 15/90, C12N2310/20, A61P 13/02, A61P 13/12, C12N 9/226, A61K 48/00, C12N2310/122, C12N2310/313, C12N2310/321, C12N2310/322Filed as Intellia Therapeutics, Inc.2025-06-23Zachary William Dymek | pending |
| Compositions and Methods for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) EditingC12N 15/1137, C12N2310/20, A61P 3/06, C12N 9/226, A61K 38/00, A61K 38/465, A61K 48/005, C12N 5/067, C12N 9/22, C12N 15/88, C12N2310/315, C12N2310/321, C12N2310/344, C12N2310/3521, C12N2310/531, C12N2320/11, C12N2320/32, C12N2510/00, C12N2800/80Filed as Intellia Therapeutics, Inc.2025-06-18Gamze Karaca | pending |
| Systems and Methods for Genomic EditingA61K 48/0058, C12N 15/102, C12N2310/20, C12N 9/226, A61K 9/1271, A61K 9/5146, A61K 48/0041, C07K2319/00, C07K2319/09, C07K2319/80, C12N 9/22, C12N 15/11, C12N 15/62, C12N 15/88, C12N 15/907Filed as Intellia Therapeutics, Inc.2025-06-18Sabin Mulepati | pending |
| METHODS FOR ANALYZING NUCLEIC ACID CARGOS OF LIPID NUCLEIC ACID ASSEMBLIESC12N 15/101, C12Q 1/6806, B01D 15/34, B01D 15/366, C12Q2565/137, G01N 30/8665, G01N 30/88, G01N2030/8827Filed as Intellia Therapeutics, Inc.2025-06-18Shreelekha Jaligama | pending |
| CD8 CO-RECEPTOR CHIMERIC POLYPEPTIDES IN TCR CELL THERAPYFiled as INTELLIA THERAPEUTICS, INC.2025-06-05BIRGIT SCHULTES | pending |
| LIPID NANOPARTICLES AND LIPID NANOPARTICLE COMPOSITIONSFiled as INTELLIA THERAPEUTICS, INC.2025-05-16ARCHANA SWAMI | pending |
| Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene EditingC12N 15/102, C12N 15/113, C12N 15/1137, C12N2310/20, A61P 13/02, A61P 13/00, C12N 9/226, A61K 9/5123, A61K 31/7088, A61K 48/0033, C12N 9/0006, C12N 9/22, C12N 15/90, C12N2310/122, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/531, C12Y 101/01027Filed as Intellia Therapeutics, Inc.2025-05-16Zachary William Dymek | pending |
| METHODS OF SYNTHESIZING AMINE LIPIDSFiled as INTELLIA THERAPEUTICS, INC.2025-04-03PHILIPP SCHNEGGENBURGER | pending |
| COMPOSITIONS AND METHODS FOR ANGIOPOIETIN LIKE 3 (ANGPTL3) EDITINGFiled as INTELLIA THERAPEUTICS, INC.2025-02-28GAMZE KARACA | pending |
| Compositions and Methods for Kallikrein (KLKB1) Gene EditingC12N 9/226, C12N 15/113, C12N2310/20, A61P 43/00, A61K 31/712, A61K 31/7125, A61K 48/0066, C12N 9/22, C12N 15/102, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3521Filed as Intellia Therapeutics, Inc.2025-01-17Shobu Odate | 12480109 |
| METHODS FOR IN VIVO EDITING OF KLKB1A61K 38/465, A61K 48/00, C12N 15/1137, C12N2310/20, A61P 7/10, A61K 9/5123, A61K 31/415, A61K 31/58, A61K 31/7105, C12N 9/22, C12Y 304/21034Filed as INTELLIA THERAPEUTICS, INC.2025-01-08David MAAG | pending |
| ENGINEERED T CELLSC07K 14/495, C12N 5/0636, A61P 37/02, A61K 40/416, A61K 40/418, A61K 40/31, A61K 40/11, A61K 35/17, C07K 14/525, C07K 14/54, C07K 14/5428, C07K 14/57, C07K 14/7051, C07K 14/70521, C07K 16/2803, C12N 5/0637, C12N 15/85, C12N2501/15, C12N2501/2302, C12N2501/2307, C12N2501/2317, C12N2501/24, C12N2501/25, C12N2510/00Filed as INTELLIA THERAPEUTICS, INC.2024-12-24Christopher RUDULIER | pending |
| CD8 Co-receptor Chimeric Polypeptides in TCR Cell TherapyFiled as Intellia Therapeutics, Inc.2024-12-20Birgit Schultes | pending |
| ENGINEERED T CELLSFiled as INTELLIA THERAPEUTICS, INC.2024-12-20CHRISTOPHER RUDULIER | pending |
| METHODS FOR RAPID ENGINEERING OF CELLSFiled as INTELLIA THERAPEUTICS, INC.2024-12-19AARON PRODEUS | pending |
| Compositions and Methods for Reducing MHC Class I in a CellA61K 40/22, C07K 14/70539, C12N 5/0636, C12N 15/1138, C12N2310/20, A61P 37/00, A61P 31/00, A61P 35/00, A61K 40/4215, A61K 40/31, A61K 40/50, A61K 40/11, C12N 9/226, C07K 14/7051, C12N 5/0696, C12N 9/22, C12N 9/78, C12N 15/11, C12N 15/907, C12N2310/315, C12N2506/115, C12N2510/00Filed as Intellia Therapeutics, Inc.2024-12-13Birgit Schultes | pending |
| Compositions and Methods for Genomic EditingA61K 35/17, C12N 15/1138, C12N2310/20, C12N 9/226, C07K 14/7051, C07K 14/70539, C12N 5/0636, C12N 9/22, C12N 9/80, C12N 15/111, C12N2310/315, C12N2310/321, C12N2310/344, C12N2310/3521, C12N2510/00Filed as Intellia Therapeutics, Inc.2024-12-13Ruan Oliveira | pending |
| Methods and Compositions for Genetically Modifying a CellA61K 48/005, C12N 15/102, C12N2310/20, A61P 35/00, C12N 9/226, A61K 35/17, C07K2319/80, C12N 5/0636, C12N 9/1258, C12N 9/22, C12N 15/111, C12N 15/113, C12N 15/88, C12Y 207/07007Filed as Intellia Therapeutics, Inc.2024-12-13Birgit Schultes | pending |
| ENGINEERED T CELLSFiled as INTELLIA THERAPEUTICS, INC.2024-12-03Christopher RUDULIER | pending |
| Lipid Nanoparticles Compositions with RibonucleoproteinsFiled as INTELLIA THERAPEUTICS, INC.2024-11-27Christopher Blanchard | pending |
| Lipid Nanoparticles and Lipid Nanoparticle CompositionsFiled as INTELLIA THERAPEUTICS, INC.2024-11-27Archana Swami | pending |
| COMPOSITIONS, METHODS, AND SYSTEMS FOR GENOMIC EDITINGFiled as INTELLIA THERAPEUTICS, INC.2024-11-08SABIN MULEPATI | pending |
| Modified Guide RNAsC12N 15/11, C12N 15/113, C12N2310/20, A61P 43/00, A61P 35/00, C12N 9/222, C12N 9/22, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/346, C12N2310/3521, C12N2310/3525, C12N2310/3533, C12N2310/531, C12N2320/51Filed as Intellia Therapeutics, Inc.2024-11-08Amy Madison Rhoden Smith | pending |
| Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisC12N 15/102, C12N 15/113, C12N2310/20, A61P 25/28, C12N 9/226, A61K 48/00, A61K 48/0041, A61K 48/005, A61K 48/0091, C07K 14/47, C12N 9/22, C12N 15/111, C12N 15/88, C12N2310/321, C12N2800/80Filed as Intellia Therapeutics, Inc.2024-11-07Arti Mahendra Prakash Kanjolia | pending |
| Compositions, Methods, and Systems for Genomic EditingFiled as Intellia Therapeutics, Inc.2024-11-04Sabin Mulepati | pending |
| Polypeptides, Polynucleotides, Compositions, and Methods for Genome Editing Involving Chromatin RemodelersFiled as Intellia Therapeutics, Inc.2024-11-04Sabin Mulepati | pending |
| CD8 Co-receptor Chimeric Polypeptides in TCR Cell TherapyFiled as Intellia Therapeutics, Inc.2024-10-25Birgit Schultes | pending |
| CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND USESA61K 35/17, C12N2310/20, A61P 35/00, A61K2239/13, A61K2239/21, A61K2239/48, A61K2239/17, A61K 40/4215, A61K 40/31, A61K 40/11, C12N 9/226, C07K 14/7051, C07K 14/70517, C07K 14/70521, C07K 16/2878, C07K2317/565, C07K2317/622, C12N 5/0636, C12N 15/111Filed as Intellia Therapeutics, Inc.2024-10-18Birgit Schultes | pending |
| NUCLEASE RESISTANT SINGLE STRANDED DNA PRODUCT FOR NON-VIRAL DELIVERY TO A CELL AND METHODS OF PRODUCTION THEREOFFiled as INTELLIA THERAPEUTICS, INC.2024-09-17VICTOR PAN | pending |
| NUCLEASE RESISTANT DOUBLE STRANDED DNA PRODUCT FOR NON-VIRAL DELIVERY TO A CELL AND METHODS OF PRODUCTION THEREOFFiled as INTELLIA THERAPEUTICS, INC.2024-09-17TAL KRAMER | pending |
| COMPOSITIONS, METHODS, AND SYSTEMS FOR GENOMIC EDITINGFiled as Intellia Therapeutics, Inc.2024-09-13Sabin Mulepati | pending |
| METHODS AND COMPOSITIONS FOR EDITING HLA-AFiled as INTELLIA THERAPEUTICS, INC.2024-08-27BIRGIT SCHULTES | pending |
| METHODS OF EDITING AN HLA-A GENE IN VITROFiled as INTELLIA THERAPEUTICS, INC.2024-08-27YONG ZHANG | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on NTLA
Company overviewEverything on NTLA in one place, with the price.SEC filingsWhat NTLA's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat NTLA's own officers and directors buy and sell.Planned salesSales NTLA insiders have filed notice of.Executive payWhat NTLA awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in NTLA.Funds holding itWhich funds and ETFs hold NTLA, and how big a bet.